Integrating cell-level kinetic modeling into the design of engineered protein therapeutics

Nature Biotechnology

Volumn 23, Issue 2, 2005, Pages 191-194

  Rao, Balaji M ^a   Lauffenburger, Douglas A ^a,b   Wittrup, K Dane ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTATIONAL METHODS; DRUG PRODUCTS; GENETIC ENGINEERING; KINETIC THEORY; MOLECULAR BIOLOGY; PROTEINS;

CELL-LEVEL KINETIC MODELING; GENOMICS; PROTEIN ENGINEERING; PROTEOMICS;

CELLS;

ANTIBODY; CYTOKINE RECEPTOR AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; PROTEIN;

CELL KINETICS; DRUG ACTIVITY; DRUG INHIBITION; DRUG METABOLISM; GENOMICS; MATHEMATICAL MODEL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEOMICS; QUANTITATIVE ANALYSIS; REVIEW; RISK REDUCTION;

CELL PHYSIOLOGY; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG THERAPY, COMPUTER-ASSISTED; GENE EXPRESSION REGULATION; KINETICS; MODELS, BIOLOGICAL; PROTEIN ENGINEERING;

EID: 13844267123     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt1064     Document Type: Review

References (58)

1. Horrobin, D.F. Realism in drug discovery-could Cassandra be right? Nat. Biotechnol. 19, 1099-1100 (2001).
2. Rees, J. Complex disease and the new clinical sciences. Science 296, 698-700 (2002).
3. Butte, A. The use and analysis of microarray data. Nat. Rev. Drug Discov. 1, 951-960 (2002).
4. Wiley, H.S., Shvartsman, S.Y. & Lauffenburger, D.A. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol. 13, 43-50 (2003).
5. Mendelsohn, J. & Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787-2799 (2003).
6. Lauffenburger, D.A. & Linderman, J.J. Receptors: Models for Binding, Trafficking, and Signaling. (Oxford University Press, Oxford, UK 1993).
7. Reddy, C.C., Niyogi, S.K., Wells, A., Wiley, H.S. & Lauffenburger, D.A. Engineering epidermal growth factor for enhanced mitogenic potency. Nat. Biotechnol. 14, 1696-1699 (1996).
8. Sarkar, C.A. et al. Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching. Nat. Biotechnol. 20, 908-913 (2002).
9. Stroud, R.M. & Wells, J.A. Mechanistic diversity of cytokine receptor signaling across cell membranes. Sci. STKE 231, RE7 (2004).
10. Brekke, O.H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2, 52-62 (2003).
11. Goffe, B. & Cather, J.C. Etanercept: an overview. J. Am. Acad. Dermatol. 49, S105-S111 (2003).
12. Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA 99, 11393-11398 (2002).
13. Pearce, K.H. Jr., Cunningham, B.C., Fuh, G., Teeri, T. & Wells, J.A. Growth hormone binding affinity for its receptor surpasses the requirements for cellular activity. Biochemistry 38, 81-89 (1999).
14. Haugh, J.M. Mathematical model of human growth hormone (hGH)-stimulated cell proliferation explains the efficacy of hgh variants as receptor agonists or antagonists. Biotechnol. Prog. 20, 1337-1344 (2004).
15. Foote, J. & Eisen, H.N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. USA 92, 1254-1256 (1995).
16. Sarkar, C.A. & Lauffenburger, D.A. Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. Mol. Pharmacol. 63, 147-158 (2003).
17. Lauffenburger, D.A., Fallon, E.M. & Haugh, J.M. Scratching the (cell) surface: cytokine engineering for improved ligand/receptor trafficking dynamics. Chem. Biol. 5, R257-R263 (1998).
18. Fallon, E.M. & Lauffenburger, D.A. Computational model for effects of ligand/receptor binding properties on interleukin-2 trafficking dynamics and T cell proliferation response. Biotechnol. Prog. 16, 905-916 (2000).
19. Smith, K.A. Cell growth signal transduction is quantal. Ann. NY Acad. Sci. 766, 263-271 (1995).
20. Li, Q.J. et al. CD4 enhances T-cell sensitivity to antigen by coordinating Lck accumulation at the immunological synapse. Nat. Immunol. 5, 791-799 (2004).
21. Goldbeter, A. & Koshland, D.E. Jr. An amplified sensitivity arising from covalent modification in biological systems. Proc. Natl. Acad. Sci. USA 78, 6840-6844 (1981).
22. Tyson, J.J., Chen, K.C. & Novak, B. Sniffers, buzzers, toggles and blinkers: dynamics of regulatory and signaling pathways in the cell. Curr. Opin. Cell Biol. 15, 221-231 (2003).
23. Schoeberl, B., Eichler-Jonsson, C., Gilles, E.D. & Muller, G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 20, 370-375 (2002).
24. Gardner, T.S., Cantor, C.R. & Collins, J.J. Construction of a genetic toggle switch in Escherichia coli. Nature 403, 339-342 (2000).
25. Angeli, D., Ferrell, J.E. Jr. & Sontag, E.D. Detection of multistability, bifurcations, and hysteresis in a large class of biological positive-feedback systems. Proc. Natl. Acad. Sci. USA 101, 1822-1827 (2004).
26. Osbourn, J., Jermutus, L. & Duncan, A. Current methods for the generation of human antibodies for the treatment of autoimmune diseases. Drug Discov. Today 8, 845-851 (2003).
27. Sanna, P.P., Ramiro-Ibanez, F. & De Logu, A. Synergistic interactions of antibodies in rate of virus neutralization. Virology 270, 386-396 (2000).
28. Vasserot, A.P. et al. Optimization of protein therapeutics by directed evolution. Drug Discov. Today 8, 118-126 (2003).
29. Forsten, K.E. & Lauffenburger, D.A. Interrupting autocrine ligand-receptor binding: comparison between receptor blockers and ligand decoys. Biophys. J. 63, 857-861 (1992).
30. Jain, R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1, 241-263 (1999).
31. Flynn, A.A. et al. A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer 94, 1249-1257 (2002).
32. Adams, G.P. et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 61, 4750-4755 (2001).
33. Graff, C.P. & Wittrup, K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63, 1288-1296 (2003).
34. Fujimori, K., Covell, D.G., Fletcher, J.E. & Weinstein, J.N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 31, 1191-1198 (1990).
35. Egrie, J.C., Dwyer, E., Browne, J.K., Hitz, A. & Lykos, M.A. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp. Hematol. 31, 290-299 (2003).
36. Chang, T.W. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol. 18, 157-162 (2000).
37. Lu, Z.Y. et al. High amounts of circulating interleukin(IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur. J. Immunol. 22, 2819-2824 (1992).
38. Montero-Julian, F.A., Klein, B., Gautherot, E. & Brailly, H. Pharmacokinetic study of anti-interleukin-6 (IL-6) therapy with monoclonal antibodies: enhancement of IL-6 clearance by cocktails of anti-IL-6 antibodies. Blood 85, 917-924 (1995).
39. Harris, J.M. & Chess, R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214-221 (2003).
40. Ashkenazi, A. & Chamow, S.M. Immunoadhesins as research tools and therapeutic agents. Curr. Opin. Immunol. 9, 195-200 (1997).
41. Dennis, M.S. et al. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. 277, 35035-35043 (2002).
42. Rao, B.M., Driver, I., Lauffenburger, D.A. & Wittrup, K.D. IL-2 variants engineered for increased IL-2R affinity exhibit increased potency arising from a cell surface ligand reservoir effect. Mol. Pharmacol. 66, 864-869 (2004).
43. Dubois, S., Mariner, J., Waldmann, T.A. & Tagaya, Y. IL-15R alpha recycles and presents IL-15 In trans to neighboring cells. Immunity 17, 537-547 (2002).
44. Giovannoni, G. Strategies to treat and prevent the development of neutralizing anti-interferon-beta antibodies. Neurology 61, S13-S17 (2003).
45. Rosenberg, A.S. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev. Biol. (Basel) 112, 15-21 (2003).
46. Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1, 457-462 (2002).
47. Patten, P.A. & Scheliekens, H. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development. Dev. Biol. (Basel) 112, 81-97 (2003).
48. Bander, N.H. et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol. 30, 667-676 (2003).
49. Wittrup, K.D. Protein engineering by cell-surface display. Curr. Opin. Biotechnol. 12, 395-399 (2001).
50. Marshall, S.A., Lazar, G.A., Chirino, A.J. & Desjarlais, J.R. Rational design and engineering of therapeutic proteins. Drug Discov. Today 8, 212-221 (2003).
51. Lazar, G.A., Marshall, S.A., Plecs, J.J., Mayo, S.L. & Desjarlais, J.R. Designing proteins for therapeutic applications. Curr. Opin. Struct. Biol. 13, 513-518 (2003).
52. Chakraborty, A.K., Dustin, M.L. & Shaw, A.S. In silico models for cellular and molecular immunology: successes, promises and challenges. Nat. Immunol. 4, 933-936 (2003).
53. Perelson, A.S. Modelling viral and immune system dynamics. Nat. Rev. Immunol. 2, 28-36 (2002).
54. Bialek, W. & Botstein, D. Introductory science and mathematics education for 21st-century biologists. Science 303, 788-790 (2004).
55. Griffith, L.G. & Grodzinsky, A.J. Advances in biomedical engineering. J. Am. Med. Assoc. 285, 556-561 (2001).
56. Grossmann, M., Leitolf, H., Weintraub, B.D. & Szkudlinski, M.W. A rational design strategy for protein hormone superagonists. Nat. Biotechnol. 16, 871-875 (1998).
57. Kortemme, T. & Baker, D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc. Natl. Acad. Sci. USA 99, 14116-14121 (2002).
58. Steed, P.M. et al. Inactivation of TNF signaling by rationally designed dominant-negative TNF variants. Science 301, 1895-1898 (2003).